Modern approaches in diagnosis and treatment of pulmonary hypertension based on recommendations of European Society of Cardiology and European Respiratory Society of recent years

Authors: Bekuraidze E.V.1, Arakelyan M.G.1, Sokolova N.Yu.2, Kazanovskaya S.N.1

Company: 1A.N. Bakoulev Scientific Center for Cardiovascular Surgery; Rublevskoe shosse, 135, Moscow, 121552, Russian Federation
2Tver' “Regional clinical hospital”; Peterburgskoe shosse, 105, Tver', Region Tver', 170036, Russian Federation

For correspondence:  Sign in or register.


DOI: https://doi.org/10.15275/kreatkard.2016.03.06

For citation: BekuraidzeE.V., Arakelyan M.G., Sokolova N.Yu., Kazanovskaya S.N.. Modern approaches in diagnosis and treatment of pulmonary hypertension based on recommendations of European Society of Cardiology and European Respiratory Society of recent years. Kreativnaya Kardiologiya. 2016; 10 (3): 239-250 (in Russian)

Keywords: pulmonary hypertension pulmonary arterial hypertension endothelin receptor antagonists calcium channel blockers phosphodiesterase type 5 inhibitors prostacyclin analogues

Полнотекстовая версия:  

 

Abstract

For many years treatment of patients with pulmonary hypertension (PH) remained unchanged. Recently, due to new drugs and increase number of controlled studies, the situation has changed considerably for the better. In this article we summarized new data on treatment of PH adapted from the updated recommendations of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) 2015 and studies of last years.

References

  1. Simonneau G., Gatzoulis M.A., Adatia I., Celermajer D., Denton C., Ghofrani A. et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2013; 62: D34–D41.
  2.  Simonneau G., Galié N., Rubin L.J., Langleben D., Seeger W., Domenighetti G. et al. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2004; 43 (Suppl. 1): S5–S12.
  3. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F. et al. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001; 358: 1119–23.
  4. Strange G., Playford D., Stewart S., Deague J.A., Nelson H., Kent A. et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart. 2012; 98 (24): 1805–11.
  5. Galié N., Olschewski H., Oudiz R.J., Torres F., Frost A., Ghofrani H.A. et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebocontrolled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008; 117: 3010–9.
  6. Olschewski H., Simonneau G., Galié N., Higenbottam T., Naeije R., Rubin L.J. et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 2002; 347: 322–9.
  7. McLaughlin V.V., Oudiz R.J., Frost A., Tapson V.F., Murali S., Channick R.N. et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2006; 174: 1257–63.
  8. Hoeper M., Leuchte H., Halank M., Wilkens H., Meyer F.J., Seyfarth H.J. et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2006; 4: 691–4.
  9. Simonneau G., Barst R.J., Galié N., Naeije R., Rich S., Bourge R.C. et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2002; 165: 800–4.
  10. Бокерия О.Л., Базарсадаева Т.С. Внезапная сер- дечная смерть и пороки митрального и аорталь- ного клапанов. Анналы аритмологии. 2013; 10 (3): 162–70. DOI: 10.15275/annaritmol.2013.3.6 / Bockeria O.L., Bazarsadaeva T.S. Sudden cardiac death and mitral and aortic valve disease. Annaly aritmologii. 2013; 10 (3): 162–70. DOI: 10.15275/ annaritmol.2013.3.6 (in Russ.).
  11. Jing Z.C., Parikh K., Pulido T., Jerjes-Sanchez C., White R.J., Allen R. et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013; 127: 624–33.
  12. Tapson V.F., Torres F., Kermeen F., Keogh A.M., Allen R.P., Frantz R.P. et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012; 142: 1383–90.
  13. Tapson V.F., Jing Z.C., Xu K.F., Pan L., Feldman J., Kiely D.G. et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013; 144: 952–8.
  14.  Simonneau G., Torbicki A., Hoeper M.M., Delcroix M., Karlocai K., Galié N. et al. Selexipag, an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur. Respir. J. 2012; 40: 874–80
  15. Humbert M., Barst R.J., Robbins I.M., Channick R.N., Galié N., Boonstra A. et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur. Respir. J. 2004; 24: 353–9.
  16. Galié N., Barbera J.A., Frost A., Ghofrani A., Hoeper M., Mc Laughlin V.V. et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N. Engl. J. Med. 2015; 373 (9): 834–44.
  17. Galié N., Humbert M., Vachieryc J.L., Gibbs S., Lang I., Torbicki A. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 2016; 37 (1): 67–119. DOI: 10.1093/eurheartj/ehv317.
  18. Galié N., Simonneau G. The Fifth World Symposium on pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2013; 62 (Suppl.): D1–D3.
  19.  Galié N., Corris P., Frost A., Girgis R., Granton J., Jing Z.C. et al. Updated treatment algorithm of pulmonary hypertension. J. Am. Coll. Cardiol. 2013; 62 (Suppl.): D60–D72.
  20. Mereles D., Ehlken N., Kreuscher S., Ghofrani S., Hoeper M.M., Halank M. et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006; 114: 1482–9.
  21. Duarte A.G., Thomas S., Safdar Z., Torres F., Pacheco L.D., Feldman J. et al. Management of pulmonary arterial hypertension during pregnancy: a retrospective, multicenter experience. Chest. 2013; 143: 1330–6.
  22. Thorne S., Nelson-Piercy C., MacGregor A.J., Gibbs S., Crowhurst J., Panay N. et al. Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J. Fam. Plann. Reprod. Health Care. 2006; 32: 75–81.
  23. Guillevin L., Armstrong I., Aldrighetti R., Howard L.S., Ryftenius H., Fischer A. et al. Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives. Eur. Respir. Rev. 2013; 22: 535–42.
  24. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med. 1992; 327: 76–81.
  25.  Cohn J.N. Optimal diuretic therapy for heart failure. Am. J. Med. 2001; 111: 577.
  26.  Sandoval J., Aguirre J.S., Pulido T., Martinez- Guerra M.L., Santos E., Alvarado P. et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am. J. Respir. Crit. Care Med. 2001; 164: 1682–7.
  27. Ruiter G., Lanser I.J., de Man F.S., Van Der Laarse W.J., Wharton J., Wilkins M.R. et al. Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology (Oxford). 2014; 53: 285–92.
  28. Rhodes C.J., Howard L.S., Busbridge M., Ashby D., Kondili E., Gibbs J.S. et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension clinical prevalence, outcomes, and mechanistic insights. J. Am. Coll. Cardiol. 2011; 58: 300–9.
  29. Viethen T., Gerhardt F., Dumitrescu D., Knoop- Busch S., ten Freyhaus H., Rudolph T.K. et al. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. Int. J. Cardiol. 2014; 175: 233–9.
  30. Sitbon O., Humbert M., Jaїs X., Ioos V., Hamid A.M., Provencher S. et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111: 3105–11.
  31.  Galié N., Humbert M., Vachieryc J.L., Gibbs S., Lang I., Torbicki A. et al. Рекомендации ESC/ERS по диагностике и лечению легочной гипертензии 2015. Российский кардиологичес- кий журнал. 2016; 5: 5–64. DOI: 10.15829/ 1560-4071-2016-5-5-64 / Galié N., Humbert M., Vachieryc J.L., Gibbs S., Lang I., Torbicki A. et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Rossiyskiy kardiologicheskiy zhurnal. 2016; 5: 5–64. DOI: 10.15829/1560-4071-2016-5-5-64 (in Russ.).
  32.  Galié N., Barbera J.A., Frost A., Ghofrani A., Hoeper M., Mc Laughlin V.V. et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N. Engl. J. Med. 2015; 3799: 834–44.
  33. Barst R.J., Chung L., Zamanian R.T., Turner M., McGoon M.D. et al. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest. 2013; 144: 160–8.
  34. Kurzyna M., Dabrowski M., Bielecki D., Fijalkowska A., Pruszczyk P., Opolski G. et al. Atrial septostomy in treatment of end-stage right heart failure in Patients with pulmonary hypertension. Chest. 2007; 131: 977–83.
  35. Sitbon O., Humbert M., Nunes H., Parent F., Garcia G., Herve P. et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 2002; 40: 780–8.
  36. McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002; 106: 1477–82.
  37.  Fadel E., Mercier O., Mussot S., Leroy-Ladurie F., Cerrina J., Chapelier A. et al. Long-term outcome of double-lung and heart–lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. Eur. J. Cardiothorac. Surg. 2010; 38: 277–84.
  38. De Perrot M., Granton J.T., McRae K., Pierre A.F., Singer L.G., Waddell T.K. et al. Outcome of patients with pulmonary arterial hypertension referred for lung transplantation: a 14-year singlecenter experience. J. Thorac. Cardiovasc. Surg. 2012; 143: 910–8.
  39. Christie J.D., Edwards L.B., Kucheryavaya A.Y., Benden C., Dipchand A.I., Dobbels F. et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heartlung transplant report – 2012. J. Heart Lung Transplant. 2012; 31: 1073–86.
  40. Trulock E.P., Edwards L.B., Taylor D.O., Trulock E.P., Waltz D.A., Keck B.M. et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart lung transplantation report – 2006. J. Heart Lung Transplant. 2006; 25: 880–92.

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, Director of Bakoulev National Medical Research Center for Cardiovascular Surgery